BlackRock Advisors’s Tempest Therapeutics TPST Stock Holding History

BlackRock Advisors’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$26K	Hold	6	–	–	﹤0.01%	3405
2016 Q3	$122K	Buy	6 +1	+20%	+$18.1K	﹤0.01%	2931
2016 Q2	$70K	Buy	5 +1	+25%	+$22.8K	﹤0.01%	3120
2016 Q1	$110K	Buy	4 +1	+33%	+$21.1K	﹤0.01%	2873
2015 Q4	$98K	Sell	3 -2	-40%	-$66K	﹤0.01%	2926
2015 Q3	$131K	Hold	5	–	–	﹤0.01%	2965
2015 Q2	$428K	Buy	5 +1	+25%	+$91.6K	﹤0.01%	2299
2015 Q1	$387K	Buy	4 +1	+33%	+$133K	﹤0.01%	2273
2014 Q4	$345K	Buy	3 +1	+50%	+$73.2K	﹤0.01%	2273
2014 Q3	$104K	Sell	2 -4	-67%	-$140K	﹤0.01%	2980
2014 Q2	$168K	Hold	6	–	–	﹤0.01%	2738
2014 Q1	$165K	Buy	6 +1	+20%	+$28.3K	﹤0.01%	2768
2013 Q4	$147K	Hold	5	–	–	﹤0.01%	2847
2013 Q3	$140K	Buy	5 +4	+400%	+$142K	﹤0.01%	2750
2013 Q2	$55K	Buy	+1	New	+$37.6K	﹤0.01%	3144

Other funds holding TPST

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CQS Cayman Camana Bay, Grand Cayman, Cayman Islands $2.26B AUM 1.31% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock Advisors's TPST Position: Q4 2016 in Review

BlackRock Advisors held its Tempest Therapeutics (TPST) position steady in Q4 2016 at 6 shares worth $26K. The position accounts for ﹤0.01% of the portfolio, ranked #3405.

BlackRock Advisors first reported a position in TPST in Q2 2013 and has held it in 15 quarters since. The position peaked at $428K in Q2 2015. 84 funds tracked by Wall St. Rank hold TPST as of Q4 2016.

BlackRock Advisors held 6 shares of Tempest Therapeutics worth $26K as of Q4 2016.
BlackRock Advisors left its Tempest Therapeutics share count unchanged in Q4 2016.
Tempest Therapeutics made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3405 holding.
BlackRock Advisors first reported a position in Tempest Therapeutics in Q2 2013 and has held it in 15 quarters since.
BlackRock Advisors's Tempest Therapeutics position peaked at $428K in Q2 2015.
84 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.